Blood tests for autoimmune hemolytic anemia in people with antiphospholipid syndrome
Uses blood tests to look for autoimmune hemolytic anemia in adults with antiphospholipid syndrome.
Key facts
- Who runs it
- New Valley University
- Where
- Egypt1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Autoimmune Hemolytic Anemia and Its Clinical Implication on Antiphospholipid Syndrome
- Status
- Recruiting
- People taking part
- 230 people, planned
- Started
- 5 Jun 2026
- Expected to end
- 15 Apr 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Hemoglobin
- Coombs test
- Record updated
- 10 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with antiphospholipid syndrome (an immune condition that causes blood clots or pregnancy problems) and anemia from red blood cell breakdown (hemolysis).
- Age
- 18 years and older
- Sex
- All sexes
- Disease stage
- Diagnosed antiphospholipid syndrome, with anemia that fits hemolysis.
Main reasons for not taking part
- Younger than 18 years
- Anemia from causes other than autoimmune hemolysis
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Adults aged ≥18 years
- Patients with anemia consistant with hemolysis
- Patient diagnosed with antiphospholipid syndrome
- Informed consent obtained
Who cannot take part
- Other causes of anemia than autoimmune hemolysis
- Age less than 18 years
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
AIHA is a heterogeneous autoimmune cytopenia with variable severity and significant morbidity. APS is defined by thrombosis and/or obstetric morbidity with persistent antiphospholipid antibodies (aPL).
The 2 groups in the trial
- Antiphospholipid syndrome patients with AIHAExisting treatment, for comparison
AIHA defined by: * Anemia plus hemolysis (↑LDH, ↑indirect bilirubin, ↓haptoglobin, reticulocytosis) and * Positive direct anti-globulin (Coombs) test , Drug induced hemolysis or other hereditary/acquired non immune hemolytic anemias.
Treatment: Hemoglobin and Coombs test
- Antiphospholipid syndrome patients without AIHAExisting treatment, for comparison
Patients without hemolysis evidence
Treatment: Hemoglobin and Coombs test
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Autoimmune Hemolytic Anemia and Its Clinical Implication on Antiphospholipid Syndrome
- Plain-language title
- Blood tests for autoimmune hemolytic anemia in people with antiphospholipid syndromeGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 10 August 2026